In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Acurx Pharmaceuticals (ACXP – Research Report), with a price target of $13.00. The company’s shares closed yesterday at $1.75.
Arce covers the Healthcare sector, focusing on stocks such as Arcturus Therapeutics, CymaBay Therapeutics, and Cidara Therapeutics. According to TipRanks, Arce has an average return of 11.9% and a 42.01% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Acurx Pharmaceuticals with a $13.00 average price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $4.61 and a one-year low of $1.53. Currently, Acurx Pharmaceuticals has an average volume of 32.66K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention, and Food and Drug Administration.
Read More on ACXP:
